Research programme: MHC class II gene modulators - Debiopharm
Alternative Names: Debio 0406; p53-69Latest Information Update: 14 Jul 2010
At a glance
- Originator GPC Biotech AG
- Developer Debiopharm
- Class Small molecules
- Mechanism of Action MHC class II gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 12 Jun 2007 Preclinical development is ongoing
- 17 Dec 2004 GPC Biotech's small molecule MHC class II antagonists programme has been licensed to Debiopharm worldwide
- 29 Aug 2002 This programme is still in active development